Compare Novavax Inc (NVAX) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SiTime Corporation — how do they compare? Novavax Inc trades at $11.09 (market cap $1.82B), while SiTime Corporation trades at $657.55 (market cap $19.42B). The key difference: SiTime Corporation is far larger — about 10.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and SiTime Corporation for 18 Days on average.
| NVAX | SITM | |
|---|---|---|
Market Cap | $1.82B | $19.42B |
Volume | 6,198,505 | 360,307 |
Sector | Health | Technology |
52-Week High | $12.56 | $901.60 |
52-Week Low | $6.22 | $252.76 |
Typical Hold Time | 59 Days | 18 Days |
Enterprise Value | $1.39B | $18.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
SITM is trading at $665.16, down 6.46% over the past 24 hours, with a bullish technical signal supported by moving averages. The company shows strong revenue growth momentum with Q2 2026 revenue surging 126.5% year-over-year to $157.43 million, marking its first GAAP profit. Analyst consensus remains strongly positive with 9 buy ratings and a $751.43 price target representing 13% upside potential. Recent institutional activity includes California State Teachers Retirement System increasing its stake by 73,098.9% during the latest quarter.
The outlook remains positive driven by AI infrastructure demand and the Renesas acquisition, though valuation metrics appear elevated with P/E at 1,076 and P/S at 36.9. Key risks include execution challenges in scaling operations and potential market volatility. The stock's current position near recent highs suggests cautious optimism is warranted despite strong growth fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
